SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Andere Sprachen Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Aktien

A0M5XT

CNE000000X38

600196

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 24.04.2024			% 5 Tage	% 1. Jan.
22.73 ^CNY	-0.09%		-0.22%	-9.19%

24.04.	Fosun Pharma-Einheit erhält Zulassungsgenehmigung für Tuberkulose-Medikament von chinesischer Aufsichtsbehörde	MT
08.04.	China akzeptiert neue Arzneimittelanträge für Medikamente von Fosun Pharma zur Behandlung des Eisenüberlastungssyndroms	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24.04.
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18.04.
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17.04.
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15.04.
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08.04.
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03.04.
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27.03.
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27.03.
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26.03.
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26.03.
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14.03.
Fosun Pharma Unit Gets China OK for Phase I Trial for Solid Tumor Drug	08.03.
Fosun Pharma Unit to Start First Phase of Trial of Cancer Drug Candidate	08.03.
Fosun Pharma Chairman Proposes Buyback of Up to 200 Million Yuan	04.03.
Fosun Pharma Subsidiaries Get Nod to Trial Leukemia Drugs	01.03.
Registration Application of Hypokalemia Drug by Shanghai Fosun Pharmaceutical Unit Accepted by Chinese Regulator	20.02.
Yuyuan Tourist Mart CFO Steps Down	05.02.
Shanghai Fosun Unit Gets Clearance For China Phase II Trial of Amyloidosis Drug	25.01.
Glycotest, Inc. announced that it has received $1 million in funding from EMV Capital Ltd, NetScientific plc, Shanghai Fosun Pharmaceutical Co., Ltd.	23.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Aktien

A0M5XT

CNE000000X38

600196

Andere Sprachen

Filter